Spear Bio Launches Ultrasensitive SPEAR Ultradetect™ to Advance Neurodegenerative Disease Research

Spear Bio’s New Solution to Modify Neurodegenerative Disease Research

Announcement

Spear Bio, a leading biotechnology company evolving homogeneous ultrasensitive immunoassay technology, has now commercially introduced SPEAR Ultradetect™ immunoassay solution. The new solution provides indifferent scalability, sensitivity, precision, and specificity for commendable biomarker measurement. The launch demonstrates four assays focusing on key neurology biomarkers named: neurofilament light (Nfl), phosphorylated tau 231 (pTau231), glial fibrillary acidic protein (GFAP), and phosphorylated tau 217 (pTau217). Spear Bio will partner with Bio-techne for the distribution of SPEAR Ultradetect immunoassays worldwide.

The solution is a new positive possibility in the neurodegenerative disease research study. Also, with the collaboration with Bio-techne, the expansion and recognition of the new solution will elevate international presence. This is an additional contribution to the expansive, innovative, and diverse healthcare market.

SPEAR Technology

Different from traditional ultrasensitive technologies that are highly dependent on heterogeneous formats requiring solid surface capture and various wash steps, the SPEAR technology is the first ever homogeneous immunoassay platform to achieve ultra-sensitivity, excluding wash steps. It specifies the number of protein biomarkers at attomolar concentrations from the samples, perfectly exceeding the sensitive heterogeneous platforms in the global healthcare market.

The SPEAR technology identifies unshakable challenges by discarding the bipolar in common heterogeneous assays, which prominently decreases false-positive results. The attractive two-factor authentication mechanism of SPEAR technology ensures the signal is visible only when antibody pairs are co-localized on target-based proteins for a longer period.

The specificity, precision, and sensitivity delivered by SPEAR ultradetect immunoassays are the main aspects for perfectly measuring low-abundance neurology biomarkers, mainly in peripheral blood, where its visible at trace levels due to blood blood-brain barrier. SPEAR Ultradetect immunoassays are readable on a broad range of qPCR systems used in clinical and research labs, with the best results through different qPCR formats and instruments. This provides excellent scalability, seamless integration, and uniqueness in the existing laboratory workflows. The SPEAR Ultradetect immunoassay solution will be presented at the Alzheimer’s Association International Conference (AAIC) 2025, on 27th July in Toronto, Canada (booth #1527).

Views and Statements

Co-founder and CEO of Spear Bio, Phd, Feng Xuan said, “We feel proud to deliver the first-ever ultrasensitive immunoassay solution that is strong enough to solve the challenges the neurology researchers face while working with blood-related biomarkers. The Spear ultradetect will encourage clinical and academic researchers globally to discover new insights and enhance treatments and therapies for several neurological conditions.”